What is Zacks Research’s Forecast for Omnicell Q4 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research upped their Q4 2024 earnings per share (EPS) estimates for shares of Omnicell in a report issued on Thursday, January 2nd. Zacks Research analyst R. Department now expects that the company will post earnings of $0.29 per share for the quarter, up from their previous estimate of $0.28. The consensus estimate for Omnicell’s current full-year earnings is $0.93 per share. Zacks Research also issued estimates for Omnicell’s Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.19 EPS and FY2026 earnings at $1.01 EPS.

Several other equities research analysts have also issued reports on OMCL. Craig Hallum lifted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Bank of America reduced their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday. JPMorgan Chase & Co. increased their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Benchmark restated a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $50.17.

Omnicell Stock Down 3.0 %

NASDAQ OMCL opened at $43.37 on Monday. The stock has a market capitalization of $2.01 billion, a PE ratio of -111.20, a price-to-earnings-growth ratio of 34.96 and a beta of 0.78. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74. The company has a 50 day moving average price of $46.25 and a two-hundred day moving average price of $40.77.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.64% of the company’s stock.

Hedge Funds Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its holdings in shares of Omnicell by 11,982.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the period. Federated Hermes Inc. lifted its stake in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after purchasing an additional 909,480 shares during the period. Sumitomo Mitsui Trust Group Inc. bought a new position in Omnicell during the third quarter worth about $32,721,000. Pacer Advisors Inc. boosted its holdings in Omnicell by 32.6% during the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after purchasing an additional 508,789 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Omnicell by 750.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after purchasing an additional 259,463 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.